Centre Hospitalier Universitaire Rouen
- Address
- lock Available on a paid plan
Centre Hospitalier Universitaire Rouen - Academic Medical Research Center
Centre Hospitalier Universitaire Rouen is a comprehensive academic medical center conducting diverse clinical research across multiple therapeutic areas. The institution demonstrates particular strength in oncology, immunology, and rare disease research, participating in numerous international multicenter trials that advance medical knowledge and treatment options for complex conditions.
- Oncology research including lung cancer, rectal cancer, pancreatic adenocarcinoma, and pediatric brain tumors with innovative targeted therapies
- Autoimmune and inflammatory conditions such as rheumatoid arthritis, vasculitis, uveitis, and dermatological disorders
- Rare diseases including Prader-Willi syndrome, Takayasu arteritis, and neuroendocrine cells hyperplasia of infancy
- Infectious disease studies focusing on ICU infections, prosthetic joint infections, and vaccination strategies
The center's research portfolio encompasses Phase II through Phase IV clinical trials, ranging from novel immunotherapies and biologics to rare disease interventions. Specialized programs address conditions such as thrombotic thrombocytopenic purpura, hidradenitis suppurativa, chronic kidney disease, and multiple sclerosis. The institution is particularly active in pediatric oncology trials for conditions like diffuse intrinsic pontine glioma (DIPG) and ependymoma, as well as dermatological research covering acne, vitiligo, urticaria, and psoriasis. Research initiatives also extend to neurological disorders including Alzheimer's disease and sickle cell disease, demonstrating the center's commitment to advancing treatment across the full spectrum of medical specialties.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 34 therapeutic areas and 15 of 605 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 563 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 107 by active trials.
lock +106 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +70 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centre Hospitalier Universitaire Rouen
lock Showing 1 of 480 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Dose-Ranging Study to Evaluate the Effects of Oral Macitentan 10 mg versus 75 mg on Endothelin-1 Clearance, Endothelial Function, and Hemodynamics in Healthy Participants | Actelion Pharmaceuticals Ltd. | Phase I | Not Recruiting | Apr 2025 | Mar 2026 |
IMP list
lock Showing 1 of 605 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Fluorouracil | 32 | Unknown | 2017-06-28 | 2026-05-07 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.